Tesaro, Inc. (TSRO) Analysts See $-2.80 EPS as of May, 8

April 17, 2018 - By Robert Reynolds

Tesaro, Inc. (NASDAQ:TSRO) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.01. That’s change of 0.20, from 2017Q3’s 1.21. 46 investors sold all, 64 reduced holdings as Tesaro, Inc. ratio is negative. 72 rose positions while 39 funds bought positions. Funds hold 57.95 million shares thus 0.57% less from 2017Q3’s 58.28 million shares.
Neuberger Berman Grp Incorporated Ltd Liability Com holds 0.01% of its capital in Tesaro, Inc. (NASDAQ:TSRO) for 148,040 shs. Moreover, Greenwood Assoc Limited Liability Corp has 0.05% invested in Tesaro, Inc. (NASDAQ:TSRO) for 2,681 shs. Capital Investors stated it has 237,000 shs or 0% of all its holdings. Natl Bank Of Montreal Can owns 9,103 shs for 0% of their capital. Toronto Dominion Comml Bank invested in 2,235 shs or 0% of the stock. Granite Point Cap Mngmt Lp has 8,100 shs. Tekla Capital Mngmt Limited Liability Company holds 57,595 shs or 0.18% of its capital. Btg Pactual Asset Mngmt Limited has invested 0.11% in Tesaro, Inc. (NASDAQ:TSRO). State Street Corporation invested in 1.41 million shs or 0.01% of the stock. Whittier Tru accumulated 12,245 shs. Principal Fincl Gru accumulated 52,934 shs. Creative Planning holds 50,209 shs. Ubs Asset Mngmt Americas Inc holds 345,305 shs or 0.02% of its capital. Jasper Ridge L P has invested 0.02% of its capital in Tesaro, Inc. (NASDAQ:TSRO). Alps Advsrs owns 60,262 shs for 0.03% of their capital.

Tesaro, Inc. had 7 selling transactions and 9 insider purchases since March 1, 2018. This’s net activity of $61.19 million. Another trade for 145,532 shs valued at $8.35M was made by SANDELL SCOTT D on Friday, March 2. On Thursday, March 1 Oliveira Orlando sold $18,488 worth of Tesaro, Inc. (NASDAQ:TSRO). 116,445 shs valued at $6.68M were bought by NEW ENTERPRISE ASSOCIATES 13 LP on Friday, March 2. MOTT DAVID M bought $8.35 million worth of stock or 145,532 shs. The insider MOULDER LEON O JR bought 5,000 shs worth $284,640. PEARSON TIMOTHY R sold $141,265 worth of stock or 2,575 shs.

Tesaro, Inc. (NASDAQ:TSRO)’s earnings report is expected by WallStreet on May, 8, RTT reports. Last year’s earnings per share was $-2.55, while now analysts expect change of 9.80 % down from current $-2.80 earnings per share. After $-3.35 EPS report last quarter, Wall Street now forecasts -16.42 % EPS growth of Tesaro, Inc.. Its shares touched $55.51 on during the last trading session after 6.22% change.Tesaro, Inc. has 1.55 million shares volume, 32.73% up from normal. TSRO is downtrending and has moved 63.82% since April 17, 2017. TSRO underperformed by 75.37% the S&P500.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Total analysts of 12 have positions in Tesaro (NASDAQ:TSRO) as follows: 9 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 75%. Since October 23, 2017 according to StockzIntelligence Inc Tesaro has 16 analyst reports. The company rating was downgraded by Piper Jaffray on Monday, October 23. On Thursday, March 1 the company was maintained by Morgan Stanley. On Wednesday, February 28 the company was maintained by Cowen & Co. On Thursday, January 18 the rating was maintained by Piper Jaffray with “Hold”. On Wednesday, January 3 the firm earned “Buy” rating by Guggenheim. On Wednesday, February 28 the rating was maintained by Credit Suisse with “Outperform”. On Wednesday, February 28 the firm earned “Buy” rating by Leerink Swann. On Wednesday, November 15 the rating was upgraded by Leerink Swann to “Outperform”. On Wednesday, November 8 the stock has “Overweight” rating by Morgan Stanley. On Wednesday, February 28 the company was maintained by Barclays Capital.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States.The firm is worth $3.04 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name.Currently it has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.